LENZ Therapeutics (LENZ) Research & Development (2020 - 2025)

LENZ Therapeutics (LENZ) has 6 years of Research & Development data on file, last reported at $3.8 million in Q3 2025.

• On a quarterly basis, Research & Development fell 41.23% year-over-year to $3.8 million in Q3 2025; TTM through Mar 2026 was $12.9 million, a 48.76% decrease from a year earlier, with the FY2025 full-year figure at $18.7 million, down 37.35% from the prior year.
• Research & Development for Q3 2025 stood at $3.8 million, down from $9.1 million in the prior quarter.
• Over the last five years, Research & Development for LENZ reached as high as $19.5 million in Q4 2023 and fell as low as $3.8 million in Q3 2025.
• Historically, Research & Development has averaged $11.5 million across 5 years, with a median of $10.5 million in 2024.
• Across the five-year window, Research & Development soared 16623.88% in 2021 and tumbled 69.96% in 2024, its largest moves.
• Year by year, Research & Development stood at $11.2 million in 2021, then surged by 64.77% to $18.5 million in 2022, then grew by 5.82% to $19.5 million in 2023, then tumbled by 69.96% to $5.9 million in 2024, then tumbled by 35.4% to $3.8 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $3.8 million in Q3 2025, $9.1 million in Q2 2025, and $5.8 million in Q1 2025.